European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2026
Patient selection in those undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases - systematic review and meta-analysis of prognostic factors in large cohorts.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liesegang Amanda, Powell Halle, Jain Anshini, Mohan Helen, Tie Jeanne, Clemons Nicholas, Michael Michael, Guerra Glen, Heriot Alexander
Аннотация
INTRODUCTION: Cytoreductive surgery (CRS) with concurrent hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment for colorectal peritoneal metastases (CPM) which can offer a median overall survival of 41 months and improve quality of life. Judicious patient selection is critical for deriving the greatest benefit and avoiding overtreatment. This meta-analysis identifies prognostic factors associated with survival in large cohorts derived from prospectively maintained databases of CRS-HIPEC patient cohorts.
MATERIALS/METHODS: A systematic review and meta-analysis was conducted to evaluate prognostic variables influencing overall survival (OS) and disease-free survival (DFS) in patients with CPM who underwent CRS-HIPEC.
RESULTS: Forty-five studies satisfied inclusion criteria for systematic review, with thirty-three studies included for qualitative synthesis. Incomplete cytoreduction, PCI, and grade III-IV complications were the strongest predictors of both OS and DFS. Tumour-specific factors associated with worse OS on pooled analysis included: poor differentiation, signet-ring cell pathology, nodal involvement, T4 stage, and rectal primary. Adjuvant/neoadjuvant systemic treatments had no significant impact on survival in this analysis. RAS mutations may be associated with poorer survival on exploratory analysis.
CONCLUSION: Survival after CRS-HIPEC was best determined by quantity of peritoneal disease (PCI) and the ability to achieve complete cytoreduction (CC-0). Major post-operative complications impact survival beyond short term morbidity. Baseline primary tumour-specific features also impacted survival.
MATERIALS/METHODS: A systematic review and meta-analysis was conducted to evaluate prognostic variables influencing overall survival (OS) and disease-free survival (DFS) in patients with CPM who underwent CRS-HIPEC.
RESULTS: Forty-five studies satisfied inclusion criteria for systematic review, with thirty-three studies included for qualitative synthesis. Incomplete cytoreduction, PCI, and grade III-IV complications were the strongest predictors of both OS and DFS. Tumour-specific factors associated with worse OS on pooled analysis included: poor differentiation, signet-ring cell pathology, nodal involvement, T4 stage, and rectal primary. Adjuvant/neoadjuvant systemic treatments had no significant impact on survival in this analysis. RAS mutations may be associated with poorer survival on exploratory analysis.
CONCLUSION: Survival after CRS-HIPEC was best determined by quantity of peritoneal disease (PCI) and the ability to achieve complete cytoreduction (CC-0). Major post-operative complications impact survival beyond short term morbidity. Baseline primary tumour-specific features also impacted survival.